Louis Moore Bacon's NGNE Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 141,636 shares of Neurogene Inc. (NGNE) worth $4.45 M, representing 0.07% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Louis Moore Bacon has initiated a new position in NGNE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Neurogene (NGNE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurogene (NGNE) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +141,636 | New Buy | 141,636 | $31.45 |
Louis Moore Bacon's Neurogene Investment FAQs
Louis Moore Bacon first purchased Neurogene Inc. (NGNE) in Q2 2026, acquiring 141,636 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Neurogene Inc. (NGNE) for 1 quarters since Q2 2026.
Louis Moore Bacon's largest addition to Neurogene Inc. (NGNE) was in Q2 2026, adding 141,636 shares worth $4.45 M.
According to the latest 13F filing for Q2 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 141,636 shares of Neurogene Inc. (NGNE), valued at approximately $4.45 M.
As of the Q2 2026 filing, Neurogene Inc. (NGNE) represents approximately 0.07% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Neurogene Inc. (NGNE) was 141,636 shares, as reported at the end of Q2 2026.